Wall Street applauded Takeda Pharmaceuticals' $8.8 billion cash bid for Millennium Pharmaceuticals, which will give the Japanese company access to a lucrative blood cancer drug and stockholders of the Cambridge, Mass. biotech firm a sweet premium on their shares.
Post new comment